PAS
RNAM

Park Avenue Securities’s Avidity Biosciences RNAM Stock Holding History

Park Avenue Securities’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,596
Closed -$244K – 1663
2025
Q3 		$244K Buy
+5,596
New +$226K ﹤0.01% 1495

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Park Avenue Securities's RNAM Position: Q4 2025 in Review

Park Avenue Securities sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 5,596 shares — an estimated $244K sold.

Park Avenue Securities first reported a position in RNAM in Q3 2025 and held it in 1 quarter. The position peaked at $244K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Park Avenue Securities reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Park Avenue Securities sold 5,596 Avidity Biosciences shares in Q4 2025, an estimated $244K.
  • Park Avenue Securities first reported a position in Avidity Biosciences in Q3 2025 and held it in 1 quarter.
  • Park Avenue Securities's Avidity Biosciences position peaked at $244K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Park Avenue Securities's 13F filing for Q4 2025, filed 5 Jan 2026.